Tiragolumab plus Tecentriq did not improve progression-free survival compared to Imfinzi in stage 3 NSCLC post-cCRT. Median progression-free survival and overall survival were similar between the ...

Sacituzumab tirumotecan (sac-TMT) significantly improved progression-free survival compared to chemotherapy in HR-positive, HER2-negative breast cancer patients. Sac-TMT reduced the risk of disease ...

Neoadjuvant Enhertu then THP improved pathological complete response rate in patients with high-risk, HER2-positive early ...

Among patients with high-risk cutaneous squamous cell carcinoma (CSCC), postsurgical treatment with Libtayo (cemiplimab-rwlc) has been found to be associated with a similar rate of second primary ...

Enhertu significantly improved IDFS compared to Kadcyla, with a 53% risk reduction in invasive disease or death in high-risk, ...

Among patients with resected stage 3B to 4 melanoma, postsurgical treatment with Opdivo (nivolumab) was associated with a ...

Among patients with small cell lung cancer (SCLC), treatment with Imdelltra (tarlatamab-dlle) was found to improve overall ...

Young female patients had a mean baseline EF of 58.3 compared with 75 for older male patients. Additionally, emotional function scores varied by disease type. When divided by cancer type and sex, the ...

Lymphoma survivors with chronic fatigue participating in a multidisciplinary intervention program experienced a beneficial ...

Imdelltra combined with chemotherapy and PD-L1 therapy showed a 71% objective response rate and 82% disease control rate in ES-SCLC patients. The safety profile was manageable, with severe ...

In the intent-to-treat population, the median progression-free survival (PFS) was 8.77 months with giredestrant plus Afinitor ...

Tagrisso combined with chemotherapy improved overall survival in EGFR-mutated NSCLC patients, including those with poor ...